PHARMABLOCK SCIENCES (NANJING), INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.33 CNY | +1.52% |
|
+0.45% | -20.22% |
| May. 20 | PharmaBlock Sciences, Inc. Approves Cash Dividend for the Year 2023 | CI |
| Apr. 24 | PharmaBlock Proposes Final Dividend for 2023 | CI |
| Sales 2024 * | 1.99B 275M | Sales 2025 * | 2.41B 333M | Capitalization | 6.23B 860M |
|---|---|---|---|---|---|
| Net income 2024 * | 236M 32.59M | Net income 2025 * | 347M 47.92M | EV / Sales 2024 * | 3.13 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.58 x |
| P/E ratio 2024 * |
26.6
x | P/E ratio 2025 * |
18
x | Employees | 2,455 |
| Yield 2024 * |
0.38% | Yield 2025 * |
0.48% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.52% | ||
| 1 week | +0.45% | ||
| 1 month | -6.89% | ||
| 3 months | +0.77% | ||
| 6 months | -28.55% | ||
| Current year | -20.22% |
1 week
30.49
31.65
1 month
30.4936.77
Current year
23.2542.30
1 year
23.2554.70
3 years
23.25210.80
5 years
23.25210.80
10 years
5.36210.80
| Managers | Title | Age | Since |
|---|---|---|---|
Min Min Yang
CEO | Chief Executive Officer | 52 | 06-12-25 |
Yi Fei Wu
DFI | Director of Finance/CFO | 45 | 21-05-31 |
Jing Wei Zhu
CTO | Chief Tech/Sci/R&D Officer | 41 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yun Bin Gao
BRD | Director/Board Member | 57 | 18-11-29 |
Min Min Yang
CEO | Chief Executive Officer | 52 | 06-12-25 |
Xu Wei Zheng
BRD | Director/Board Member | 60 | 19-11-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 31.33 | +1.52% | 3,274,403 |
| 24-05-30 | 30.86 | -0.45% | 2,119,392 |
| 24-05-29 | 31 | -0.45% | 2,300,500 |
| 24-05-28 | 31.14 | -0.54% | 2,669,586 |
| 24-05-27 | 31.31 | +0.38% | 2,754,760 |
End-of-day quote Shenzhen S.E., May 30, 2024
More quotes
PharmaBlock Sciences Nanjing Inc is a company mainly engaged in design, synthesis and sales of pharmaceutical molecular building blocks. The Company's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The Company is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
31.33
CNY
Average target price
40
CNY
Spread / Average Target
+27.67%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.22% | 860M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- 300725 Stock
